| Description |
1 online resource (ii, 38 p.) : ill. |
| Note |
Title from title caption (GAO, viewed Apr. 19, 2010). |
|
"January 2010." |
| File Type |
Text in PDF format. |
| Summary |
The Food and Drug Administration (FDA) is responsible for protecting public health by regulating products such as prescription drugs and vaccines and has the authority to investigate alleged criminal activity related to FDA-regulated products, for example on the sale of counterfeit drugs. Within FDA, the Office of Criminal Investigations (OCI) investigates individuals and companies external to FDA. FDA also has the authority to investigate allegations of FDA employee misconduct and these internal investigations are conducted by the Office of Internal Affairs (OIA), a distinct office within OCI. GAO was asked to examine FDA's (1) oversight of OCI investigations, (2) oversight of OIA investigations, and (3) funding, staffing, and workload for OCI. GAO interviewed agency officials, reviewed FDA documents including those describing its investigative policies, and examined FDA data on OCI resources and workload, from fiscal years 1999 to 2008. |
| Bibliography |
Includes bibliographical references. |
| Note |
"GAO-10-221." |
| Subject |
United States. Food and Drug Administration. Office of Internal Affairs -- Rules and practice.
|
|
Criminal investigation -- United States.
|
|
United States -- Officials and employees -- Discipline.
|
|
Governmental investigations -- United States.
|
|
United States. Food and Drug Administration. |
|
Product Recalls and Withdrawals -- legislation & jurisprudence -- United States. |
|
Fraud -- legislation & jurisprudence -- United States. |
|
Government Regulation -- United States. |
| Added Author |
United States. Congress. Senate. Committee on Finance.
|
| Added Title |
Improved monitoring and development of performance measures needed to strengthen oversight of criminal and misconduct investigations |
| Running Title |
Criminal and misconduct investigations |
| Gpo Item No. |
0546-D (online) |
| Sudoc No. |
GA 1.13:GAO-10-221 |
|
